Osimertinib Medication Usage Guidelines and Instructions

Indications:

Non-small cell lung cancer: Osimertinib is suitable for first-line treatment of patients with squamous cell carcinoma who have not been treated or failed treatment, as well as patients with advanced non-small cell lung cancer who have sensitive mutations in the EGFR gene.

Adjuvant treatment for postoperative lung cancer: Osimertinib can be used for IB-IIIA stage EGFRexon19 Postoperative adjuvant treatment for non-small cell lung cancer patients with deletions or exon 21 (L858R) substitution mutations. Patients must have previously undergone surgical resection, and the doctor will decide whether to accept adjuvant chemotherapy or not.

Mechanism of action:

Osimertinib is a tyrosine kinase inhibitor that exerts anti-tumor effects mainly by inhibiting the tyrosine kinase activity of epidermal growth factor receptor (EGFR). Specifically, osimertinib can block the conduction of the EGFR signaling pathway, inhibit the proliferation, differentiation and growth of tumor cells, induce tumor cell apoptosis, and reduce their spread to surrounding tissues and organs. EGFR is overexpressed in a variety of tumor cells and is one of the important driving factors for tumor growth and metastasis. Therefore, osimertinib can effectively control tumor growth and metastasis by inhibiting the activity of EGFR.

Medication method:

The recommended dose for adults is once daily80mg

Side effects:

Skin reaction: Osimertinib may cause bullous dermatosis on the skin, which is manifested as blisters on normal skin or erythema. Symptoms such as erosion, scabs, and desquamation may occur after the blisters rupture. In addition, it may also cause skin blackening all over the body, oral inflammation, as well as symptoms such as rash, dry skin, skin itching, pain, and lacerations.

Digestive system abnormalities: Osimertinib can cause digestive system symptoms and injuries such as oral ulcers, loss of appetite, abdominal pain, diarrhea, bloody stools, constipation, emphysema, and abnormal liver function.

Respiratory system problems: Interstitial lung disease and pneumonia are common complications after the use of osimertinib. The mechanism may be that while osimertinib inhibits tumor growth, it also inhibits the growth and damage repair of tracheal epithelial cells, thus aggravating lung damage.

Cardiovascular system effects: Osimertinib inhibits PI3K signaling, a gene that can prolong the aging process of the heart, causing prolongation of the QT interval on the electrocardiogram. If treatment is not received in time, patients may suffer from severe reactions such as frequent syncope and cardiac arrest. In addition, it may also cause conditions such as decreased cardiac ejection fraction, heart failure, and myocarditis.

In addition to the above side effects, osimertinib may also cause bone marrow suppression (such as leukopenia, anemia, thrombocytopenia, etc.), eye abnormalities (such as dry eyes, blurred vision, keratitis, cataracts, etc.), fatigue, weight loss, muscle pain and other adverse reactions.

Warnings and precautions:

During the period of taking the medicine, patients should go to the hospital for regular check-ups to understand the recovery of the condition and pay close attention to their symptoms. If serious side effects occur, the doctor should be informed in time so that the doctor can adjust the treatment plan according to the specific situation.

Drug interactions:

Interactions with Enzyme Inducers: Osimertinib may interact with some drugs, including enzyme inducers. Enzyme inducers promote the activity of specific metabolic enzymes in the liver and reduce the concentrations of other drugs in the body.

Interactions with enzyme inhibitors: Osimertinib may also interact with some drugs, including enzyme inhibitors. Enzyme inhibitors inhibit specific drug metabolism pathways, thereby increasing the concentrations of other drugs in the body.

Medication for special populations:

Pregnant and lactating women, the elderly and those with liver and kidney damage: Please use with caution.